Kintara Therapeutics, Inc. (KTRA) Stock Overview
Explore Kintara Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Kintara Therapeutics, Inc. (KTRA)
Key Financials
Key Financials
Market Cap
12M
P/E Ratio
-0.34
EPS (TTM)
$-11.20
ROE
-1.51%
KTRA Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Kintara Therapeutics, Inc. (NASDAQ: KTRA) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Kintara Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of KTRA on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $0.00 for the NASDAQ listing.
Key metrics behind Kintara Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -0.34 and a market capitalization of 12M. Combined with our AI analysis, these give both institutional and retail investors a clear view of KTRA on the NASDAQ.